CRISM THERAPEUTICS CORPORATION (CRTX) — Interim Results

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the CRISM THERAPEUTICS CORPRATION INTERMESTS PRESENTATION. Throughout this quarter presentation, investors will be in listen only mode. Questions are encouraged and they can be submitted at any time by the Q and A tab situated in the right corner of your screen. Just simply type in your questions and press send. The company may not be in a position to answer every question received in the meeting itself. However, the company can view all the questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to split the following poll. I'd now like to hand you to CEO, Andrew Webb. Good afternoon to you, sir. Thanks, Alexandre. Good afternoon. Thank you for taking taking the time to join today's presentation. My name is Andrew Webb. I'm chief executive of CRISM THERAPEUTICS. And, and, today's presentation, we'll be looking to really reflect on the highlights from the interim results that we we we posted yesterday. And following that, I really want to take some time to look at the important development for the company, and that's our movement now into commencement of clinical trials. So in order to take take that forward, and, I'm not looking so I'm joined today by, professor Garth Kupshank. Professor Kupshank is professor of neurosurgery at the University Hospital in Birmingham. And Vascula Shank, if you could just take perhaps a couple of minutes to to introduce yourself, that'll be that'll be helpful. Hi, Andrew. Thanks very much, and welcome to everybody. Yes. So I I'm Emeritus professor of neurosurgery in Birmingham. I've been involved with the treatment of glioblastoma for well over thirty years or so, and I've been heavily involved in the development of trials, which have really focused in on...